Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS). Chen, J., Johnson, L., McKenna, K., Choi, T. S., Duan, J., Feng, D., Tsai, J. M., Garcia-Martin, N., Sompalli, K., Maute, R., Vyas, P., Majeti, R., Takimoto, C. M., Liu, J., Ramsingh, G., Chao, M., Volkmer, J., Weissman, I. L. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for Web of Science ID 000863680301955